The cellular and developmental biology of medulloblastoma: Current perspectives on experimental therapeutics

Cancer Biology and Therapy

Volumn 9, Issue 11, 2010, Pages 843-852

  Srivastava, Vinit Krishna ^a   Nalbantoglu, Josephine ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Cancer stem cell; Cerebellum; Medulloblastoma; Molecular therapeutics; Signal transduction

Indexed keywords

CANCER GROWTH; CANCER RESEARCH; CANCER STEM CELL; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CEREBELLUM CORTEX; GRANULE CELL; HISTOPATHOLOGY; HUMAN; MEDULLOBLASTOMA; NONHUMAN; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; CEREBELLAR NEOPLASMS; HISTONE DEACETYLASES; HUMANS; MEDULLOBLASTOMA; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION;

EID: 77954397956     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.11.11785     Document Type: Review

References (91)

1. Modha A, Vassilyadi M, George A, Kuehn S, Hsu E, Ventureyra ECG. Medulloblastoma in children - the Ottawa experience. Childs Nerv Syst 2000; 16:341-50.
2. Wang VY, Zoghbi HY. Genetic regulation of cerebellar development. Nat Rev Neurosci 2001; 2:484-91.
3. Wechsler-Reya RJ, Scott MP. Control of neuronal precursor proliferation in the cerebellum by sonic hedgehog. Neuron 1999; 22:103-14.
4. Lewis PM, Gritli-Linde A, Smeyne R, Kottmann A, McMahon AP. Sonic hedgehog signaling is required for expansion of granule neuron precursors and patterning of the mouse cerebellum. Dev Biol 2004; 270:393-410.
5. Ruiz I, Altaba A, Palma V, Dahmane N. Hedgehog-GLI signaling and the growth of the brain. Nat Rev Neurosci 2002; 3:24-33.
6. Johnson RL, Rothman AL, Xie J, Goodrich LV, Bare JW, Bonifas JM, et al. Human homolog of 'patched,' a candidate gene for the basal cell nevus syndrome. Science 1996; 272:1668-71.
7. Goodrich LV, Img SRC, Higgins KM, Scott MP. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997; 277:1109-13.
8. Wang JY, Del Valle L, Gordon J, Rubini M, Romano G, Croul S, et al. Activation of the IGF-IR system contributes to malignant growth of human and mouse medulloblastomas. Oncogene 2001; 20:3857-68.
9. Linseman DA, Phelps RA, Bouchard RJ, Le SS, Laessig TA, McClure ML, et al. Insulin-like growth factor-I blocks bcl-2 interacting mediator of cell death (Bim) induction and intrinsic death signaling in cerebellar granule neurons. J Neurosci 2002; 22:9287-97.
10. Dansen TB, Burgering BMT. Unravelling the tumor-suppressive functions of FOXO proteins. Trends Cell Biol 2008; 18:421-9.
11. Srivastava VK, Yasruel Z, Nalbantoglu J. Impaired medulloblastoma cell survival following activation of the FOXO1 transcription factor. Int J Oncol 2009; 35:1045-51.
12. Adesina AM, Nguyen Y, Mehta V, Takei H, Stangeby P, Crabtree S, et al. FOXG1 dysregulation is a frequent event in medulloblastoma. J Neurooncol 2007; 85:111-22.
13. Solecki DJ, Liu X, Tomoda T, Fang Y, Hatten ME. Activated notch2 signaling inhibits differentiation of cerebellar granule neuron precursors by maintaining proliferation. Neuron 2001; 31:557-68.
14. Stump G, Durrer A, Klein AL, Lutolf S, Suter U, Taylor V. Notch1 and its ligands delta-like and jagged are expressed and active in distinct cell populations in the postnatal mouse brain. Mech Dev 2002; 114:153-9.
15. Fan X, Mikolaenko I, Elhassan I, Ni X, Wang Y, Ball D, et al. Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res 2004; 64:7787-93.
16. Rio C, Rieff HI, Qi P, Corfas G. Neuregulin and erbB receptors play a critical role in neuronal migration. Neuron 1997; 19:39-50.
17. Gilbertson RJ, Clifford SC, MacMeekin W, Wright C, Perry RH, Kelly P, et al. Expression of the erbB-neuregulin signaling network during human cerebellar development: implications for the biology of medulloblastoma. Cancer Res 1998; 58:3932-41.
18. Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 2001; 3:245-52.
19. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002; 2:764-76.
20. Grotzer MA, Hogarty MD, Janss AJ, Liu X, Zhao H, Eggert A, et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clinical Cancer Research 2001; 7:2425-33.
21. Herms J, Neidt I, Lscher B, Schrmann P, Schrder T, Bergmann M, et al. C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer 2000; 89:395-402.
22. De Bortoli M, Castellino R, Lu X-Y, Deyo J, Sturla L, Adesina A, et al. Medulloblastoma outcome is adversely associated with overexpression of EEF1D, RPL30 and RPS20 on the long arm of chromosome 8. BMC Cancer 2006; 6:223-35.
23. Eberhart CG, Kratz J, Wang Y, Summers K, Stearns D, Cohen K, et al. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC and anaplasia. J Neuropath Exp Neurol 2004; 63:441-9.
24. Takei H, Nguyen Y, Mehta V, Chintagumpala M, Dauser RC, Adesina AM. Low-level copy gain versus amplification of myc oncogenes in medulloblastoma: utility in predicting prognosis and survival. J Neurosurg Pediatr 2009; 3:61-5.
25. Kim JY, Sutton ME, Lu DJ, Cho TA, Goumnerova LC, Goritchenko L, et al. Activation of neurotrophin-3 receptor TrkC induces apoptosis in medulloblastomas. Cancer Res 1999; 59:711-9.
26. Grotzer MA, Janss AJ, Fung KM, Biegel JA, Sutton LN, Rorke LB, et al. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. Journal of Clinical Oncology 2000; 18:1027-35.
27. Segal RA, Goumnerova LC, Kwon YK, Stiles CD, Pomeroy SL. Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci USA 1994; 91:12867-71.
28. Boon K, Eberhart CG, Riggins GJ. Genomic amplification of orthodenticle homologue 2 in medulloblastomas. Cancer Res 2005; 65:703-7.
29. de Haas T, Oussoren E, Grajkowska W, Perek-Polnik M, Popovic M, Zadravec-Zaletel L, et al. OTX1 and OTX2 expression correlates with the clinicopathologic classification of medulloblastomas. J Neuropath Exp Neurol 2006; 65:176-86.
30. Di C, Liao S, Adamson DC, Parrett TJ, Broderick DK, Shi Q, et al. Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Cancer Res 2005; 65:919-24.
31. Frantz GD, Weimann JM, Levin ME, McConnell SK. Otx1 and Otx2 define layers and regions in developing cerebral cortex and cerebellum. J Neurosci 1994; 14:5725-40.
32. Adamson DC, Shi Q, Wortham M, Northcott PA, Di C, Duncan CG, et al. OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas. Cancer Res 2010; 70:181-91.
33. Hahn H, Wojnowski L, Specht K, Kappler R, Calzada-Wack J, Potter D, et al. Patched target igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J Biol Chem 2000; 275:28341-4.
34. Rao G, Pedone CA, Del Valle L, Reiss K, Holland EC, Fults DW. Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. Oncogene 2004; 23:6156-62.
35. Hallahan AR, Pritchard JI, Hansen S, Benson M, Stoeck J, Hatton BA, et al. The smoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res 2004; 64:7794-800.
36. Dakubo GD, Mazerolle CJ, Wallace VA. Expression of notch and wnt pathway components and activation of notch signaling in medulloblastomas from heterozygous patched mice. J Neurooncol 2006; 79:221-7.
37. Lee Y, Miller HL, Jensen P, Hernan R, Connelly M, Wetmore C, et al. A molecular fingerprint for medulloblastoma. Cancer Res 2003; 63:5428-37.
38. Wetmore C, Eberhart DE, Curran T. Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Cancer Research 2001; 61:513-6.
39. Altman J, Bayer SA. Development of the cerebellar system: in relation to its evolution, structure and functions. New York: CRC Press 1997.
40. Zhang L, Goldman JE. Generation of cerebellar interneurons from dividing progenitors in white matter. Neuron 1996; 16:47-54.
41. Lee A, Kessler JD, Read TA, Kaiser C, Corbeil D, Huttner WB, et al. Isolation of neural stem cells from the postnatal cerebellum. Nat Neurosci 2005; 8:723-9.
42. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996; 183:1797-806.
43. Hulspas R, Quesenberry PJ. Characterization of neurosphere cell phenotypes by flow cytometry. Cytometry 2000; 40:245-50.
44. Islam MO, Kanemura Y, Tajria J, Mori H, Kobayashi S, Hara M, et al. Functional expression of ABCG2 transporter in human neural stem/progenitor cells. Neurosci Res 2005; 52:75-82.
45. Islam MO, Kanemura Y, Tajria J, Mori H, Kobayashi S, Shofuda T, et al. Characterization of ABC transporter ABCB1 expressed in human neural stem/progenitor cells. FEBS Letters 2005; 579:3473-80.
46. Kim M, Morshead CM. Distinct populations of forebrain neural stem and progenitor cells can be isolated using side-population analysis. J Neurosci 2003; 23:10703-9.
47. Mouthon MA, Fouchet P, Mathieu C, Sii-Felice K, Etienne O, Lages CS, et al. Neural stem cells from mouse forebrain are contained in a population distinct from the 'side population'. J Neurochem 2006; 99:807-17.
48. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63:5821-8.
49. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature 2004; 432:396-401.
50. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004; 101:14228-33.
51. Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 2004; 101:781-6.
52. Fan X, Matsui W, Khaki L, Stearns D, Chun J, Li YM, et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 2006; 66:7445-52.
53. Srivastava VK, Nalbantoglu J. Flow cytometric characterization of the DAOY medulloblastoma cell line for the cancer stem-like phenotype. Cytometry A 2008.
54. Read T-A, Fogarty MP, Markant SL, McLendon RE, Wei Z, Ellison DW, et al. Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell 2009; 15:135-47.
55. + cancer stem cells in patched-1-deficient mouse medulloblastoma. Cancer Res 2009; 69:4682-90.
56. Pfenninger CV, Roschupkina T, Hertwig F, Kottwitz D, Englund E, Bengzon J, et al. CD133 is not present on neurogenic astrocytes in the adult subventricular zone, but on embryonic neural stem cells, ependymal cells and glioblastoma cells. Cancer Res 2007; 67:5727-36.
57. Schüller U, Heine VM, Mao J, Kho AT, Dillon AK, Han Y-G, et al. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form shh-induced medulloblastoma. Cancer Cell 2008; 14:123-34.
58. Yang Z-J, Ellis T, Markant SL, Read T-A, Kessler JD, Bourboulas M, et al. Medulloblastoma can be initiated by deletion of patched in lineage-restricted progenitors or stem cells. Cancer Cell 2008; 14:135-45.
59. Gray SG, Ekstrom TJ. The human histone deacetylase family. Exp Cell Res 2001; 262:75-83.
60. Furchert SE, Lanvers-Kaminsky C, Juürgens H, Jung M, Loidl A, Frühwald MC. Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 2007; 120:1787-94.
61. Shu Q, Antalffy B, Su JMF, Adesina A, Ou CN, Pietsch T, et al. Valproic acid prolongs survival time of severe combined immunodeficient mice bearing intracerebellar orthotopic medulloblastoma xenografts. Clin Cancer Res 2006; 12:4687-94.
62. Children's Oncology Group; National Cancer Institute. Valproic acid in treating young patients with recurrent or refractory solid tumors or CNS tumors. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2010]. Available from: http://clinicaltrials.gov/show/ NCT00107458 NLM Identifier: NCT00107458.
63. Kelly W, Richon VM, O'Connor O, Curley T, Gregor-Curtelli B, Tong W, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003; 9:3578-88.
64. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005; 23:3923-31.
65. Spiller SE, Ditzler SH, Pullar BJ, Olson JM. Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA). J Neurooncol 2008; 87:133-41.
66. Spiller SE, Ravanpay AC, Hahn AW, Olson JM. Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma. J Neurooncol 2006; 79:259-70.
67. Children's Oncology Group; National Cancer Institute. Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma or Leukemia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2010]. Available from: http://clinicaltrials.gov/show/NCT00217412 NLM Identifier: NCT00217412.
68. Pediatric Brain Tumor Consortium; National Cancer Institute. Vorinostat, Isotretinoin, and Combination Chemotherapy in Treating Young Patients Who Have Undergone Surgery for Embryonal Tumors of the Central Nervous System. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2010]. Available from: http://clinicaltrials.gov/show/NCT00867178 NLM Identifier: NCT00867178.
69. Berman DM, Karhadkar SS, Hallahan AR, Pritchard JI, Eberhart CG, Watkins DN, et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 2002; 297:1559-61.
70. Lauth M, Bergstrom A, Shimokawa T, Toftgard R. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci USA 2007; 104:8455-60.
71. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009; 361:1173-8.
72. Yauch RL, Dijkgraaf GJP, Alicke B, Januario T, Ahn CP, Holcomb T, et al. Smoothened mutation confers resistance to a hedgehog pathway inhibitor in medulloblastoma. Science 2009; 326:572-4.
73. Pediatric Brain Tumor Consortium; National Cancer Institute. GDC-0449 in Treating Adult Patients With Recurrent or Refractory Medulloblastoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2010]. Available from: http://clinicaltrials.gov/show/NCT00939484 NLM Identifier: NCT00939484.
74. Pediatric Brain Tumor Consortium; National Cancer Institute. GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2010]. Available from: http://clinicaltrials.gov/show/NCT00822458 NLM Identifier: NCT00822458.
75. Diede SJ, Guenthoer J, Geng LN, Mahoney SE, Marotta M, Olson JM, et al. DNA methylation of developmental genes in pediatric medulloblastomas identified by denaturation analysis of methylation differences. Proc Natl Acad Sci USA 2010; 107:234-9.
76. Ecke I, Petry F, Rosenberger A, Tauber S, Monkemeyer S, Hess I, et al. Antitumor Effects of a Combined 5-Aza-2'Deoxycytidine and Valproic Acid Treatment on Rhabdomyosarcoma and Medulloblastoma in Ptch Mutant Mice. Cancer Res 2009; 69:887-95.
77. Garcia-Echeverria C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J, et al. In vivo antitumor activity of NVP-AEW541-A novel, potent and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004; 5:231-9.
78. Urbanska K, Trojanek J, Del Valle L, Eldeen MB, Hofmann F, Garcia-Echeverria C, et al. Inhibition of IGF-I receptor in anchorage- independence attenuates GSK-3[beta] constitutive phosphorylation and compromises growth and survival of medulloblastoma cell lines. Oncogene 2006; 26:2308-17.
79. Pediatric Brain Tumor Consortium; National Cancer Institute. Lapatinib in Treating Young Patients With Recurrent or Refractory CNS Tumors. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2010]. Available from: http://clinicaltrials.gov/show/NCT00095940 NLM Identifier: NCT00095940.
80. Freemantle SJ, Spinella MJ, Dmitrovsky E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 2003; 22:7305-15.
81. Chang Q, Chen Z, You J, McNutt MA, Zhang T, Han Z, et al. All-trans-retinoic acid induces cell growth arrest in a human medulloblastoma cell line J Neurooncol 2007; 84:263-7.
82. Gumireddy K, Sutton LN, Phillips PC, Reddy CD. All-trans-retinoic acid-induced apoptosis in human medulloblastoma. Clin Cancer Res 2003; 9:4052-9.
83. Hallahan AR, Pritchard JI, Chandraratna RAS, Ellenbogen RG, Geyer JR, Overland RP, et al. BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat Med 2003; 9:1033-8.
84. New York University School of Medicine; Children's Hospitals and Clinics of Minnesota; Schneider Children's Hospital. Temozolomide, Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-Cis-Retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2010]. Available from: http://clinicaltrials.gov/show/NCT00528437 NLM Identifier: NCT00528437.
85. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444:756-60.
86. Lou H, Dean M. Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene 2007; 26:1357-60.
87. Northcott PA, Rutka JT, Taylor MD. Genomics of medulloblastoma: from Giemsa-banding to next-generation sequencing in 20 years. Neurosurg Focus 2010; 28:6.
88. Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, et al. Outcome prediction in pediatric medulloblastoma based on DNA copy- number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 2009; 27:1627-36.
89. Wingate RJ. The rhombic lip and early cerebellar development. Curr Opin Neurobiol 2001; 11:82-8.
90. Behesti H, Marino S. Cerebellar granule cells: insights into proliferation, differentiation, and role in medulloblastoma pathogenesis. Int J Biochem Cell Biol 2009; 41:435-45.
91. Hoffmann R, Valencia A. A gene network for navigating the literature. Nat Genet 2004; 36:664.